A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 503.77% and ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly expects its experimental weight loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks told Bloomberg Jan. 13, according to a Wall Street Journal report.

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

In the company's third-quarter report in October, Lilly reported sales of both Mounjaro and Zepbound that missed expectations, as wholesalers cut inventory after bulking up on supply in the previous ...

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

As for its other main weight-loss drug, Zepbound, the firm estimated that it had brought in $1.9 billion, versus the mean ...